Stocks are responding to the deal with Iran, as Orexigen clears safety hurdle for its obesity drug Contrave. Adam Feuerstein gives details.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source























